tndm-ex991

San Diego, July 30, 2015 – Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim® and t:flex™ Insulin Pumps, today reported its financial results for the quarter ended June 30, 2015.

“Our strong sales momentum continued in the second quarter, which was highlighted by our successful launch of the t:flex Pump,” said Kim Blickenstaff, President and Chief Executive Officer of Tandem Diabetes Care. “This launch marks our achievement of a strategic Company goal to leverage our infrastructure by offering multiple products that address different needs of the diabetes community.”

Gross margin was 31 percent for the quarter ended June 30, 2015 compared to 34 percent in the same period of 2014.

For the second quarter of 2015, operating expenses increased 8 percent to $23.5 million from $21.8 million for the same period of 2014.

Operating loss for the second quarter of 2015 was $18.7 million, compared to $18.3 million for the same period of 2014. This included non-cash, stock-based compensation of $3.3 million for the quarter ended June 30, 2015, compared to $3.5 million for the same period of 2014.

As of June 30, 2015, the Company had $99.7 million in cash, cash equivalents and short-term investments.

The Company will hold a conference call and simultaneous webcast today at 5:30pm Eastern Time (2:30pm Pacific Time). The link to the webcast will be available by accessing the Investor Center of the Tandem Diabetes Care website at http://investor.tandemdiabetes.com, and will be archived for 30 days. To listen to the conference call via phone, please dial 855-427-4396 (U.S./Canada) or 484-756-4261 (International) and use the participant code "81630278".

About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells the t:slim Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, and the t:flex Insulin Pump, the first pump designed for people with greater insulin requirements. Tandem is based in San Diego, California.

t:flex is a trademark, and t:slim and Tandem Diabetes Care are registered trademarks of Tandem Diabetes Care, Inc.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to the Company’s projected financial results, the Company’s ability to offer multiple products to leverage its infrastructure and achieve operating efficiencies, and the Company’s ability to sustain sales momentum for during the remainder of 2015. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, successful commercialization of the Company’s products may be negatively impacted by lack of market acceptance by physicians and people with diabetes and customers may delay purchasing decisions for the Company’s existing products until the t:slim G4 Insulin Pump is commercially available. Other risks and uncertainties include the Company’s inability to manufacture products in commercial quantities at an acceptable cost and in accordance with quality requirements; the Company’s inability to contract with additional third-party payors for reimbursement of the Company’s products; possible delays in the Company’s product development programs; possible future actions of the U.S. Food and Drug Administration or any other regulatory body or governmental authority; and other risks identified in the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.

TANDEM DIABETES CARE, INC.
CONDENSED BALANCE SHEETS
(in thousands)
	June 30,		December 31,
	2015		2014
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents and short-term investments	$	97,746	$	67,282
Restricted cash		2,000		2,000
Accounts receivable, net		7,473		7,652
Inventory, net		14,670		11,913
Other current assets		2,170		1,904
Total current assets		124,059		90,751

Property and equipment, net		14,325		12,581
Other long term assets		2,950		3,132
Total assets	$	141,334	$	106,464
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable, accrued expense and employee-related liabilities	$	14,590	$	14,591
Deferred revenue		1,038		840
Other current liabilities		2,857		2,663
Total current liabilities		18,485		18,094

Notes payable-long-term		29,479		29,440
Other long-term liabilities		5,618		4,358
Total liabilities		53,582		51,892

Total stockholders’ equity		87,752		54,572
Total liabilities and stockholders’ equity	$	141,334	$	106,464

TANDEM DIABETES CARE, INC.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Sales	$	15,706		$	10,255		$	28,014		$	18,320
Cost of sales		10,905			6,806			20,406			14,005
Gross profit		4,801			3,449			7,608			4,315

Operating expenses:
Selling, general and administrative		19,599			18,068			38,954			36,109
Research and development		3,873			3,699			7,735			7,362
Total operating expenses		23,472			21,767			46,689			43,471
Operating loss		(18,671	)		(18,318	)		(39,081	)		(39,156	)

Other income (expense), net:
Interest and other income		61			31			160			49
Interest and other expense		(923	)		(910	)		(1,821	)		(2,052	)
Total other income (expense), net		(862	)		(879	)		(1,661	)		(2,003	)
Net loss	$	(19,533	)	$	(19,197	)	$	(40,742	)	$	(41,159	)

Net loss per share, basic and diluted	$	(0.65	)	$	(0.83	)	$	(1.47	)	$	(1.79	)

Weighted average shares used to compute basic and diluted net loss per share		29,902			23,098			27,723			23,017